Genetically encoded self-assembling affibody-streptavidin nanoparticles for HER2-positive cancer theranostics

Key Points

• Nanoparticles targeted HER2-positive cancer cells, improving theranostic outcomes.
• The use of self-assembling affibody-streptavidin nanoparticles showed a significant enhancement in targeting efficiency.
• Assessment through a systematic approach revealed effective binding and stability of these nanoparticles.
• This strategy may highlight improvements in cancer treatment precision, though clinical validation is necessary.